Using bionanotechnology to improve lung cancer treatment
Bionanotechnology approach for treatment of lung cancer
This study is testing a new way to treat non-small cell lung cancer by combining special tiny molecules with regular chemotherapy to make it work better and have fewer side effects, all while delivering the treatment directly to the lungs for more effective results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10553243 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for Non-Small Cell Lung Carcinoma (NSCLC), the most common type of lung cancer. It aims to enhance the effectiveness of chemotherapy by using a combination of small interfering RNAs to target specific cancer pathways, alongside traditional anticancer drugs. The treatment will be delivered directly to the lungs to improve drug accumulation and reduce side effects. By targeting cancer cells more precisely, the goal is to increase the number of patients who benefit from this therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Non-Small Cell Lung Carcinoma who have not responded well to existing treatments.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for lung cancer patients.
How similar studies have performed: Other research has shown promise in using targeted therapies and localized drug delivery for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Minko, Tamara — Rutgers Biomedical and Health Sciences
- Study coordinator: Minko, Tamara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.